Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.70 |
| ▸ | CA2 | P00918 | 1/20 | 0.70 |
| ▸ | CA9 | Q16790 | 1/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 14/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7095475 | 0.98 | CA12 (0.68) | CA12CA2CA9ALOX15ALDH1A1 | |
| SCHEMBL3905679 | 0.98 | CA12 (0.72) | CA12CA2CA9ALOX15ALDH1A1 | |
| SCHEMBL472226 | 0.97 | CA12 (0.70) | CA12CA2CA9ALOX15ALDH1A1 | |
| SCHEMBL3898192 | 0.97 | CA12 (0.70) | CA12CA2CA9ALOX15ALDH1A1 | |
| SCHEMBL7095728 | 0.97 | CA12 (0.66) | CA12CA2CA9ALOX15ALDH1A1 | |
| SCHEMBL7097556 | 0.95 | CA12 (0.64) | CA12CA2CA9ALOX15ALDH1A1 | |
| SCHEMBL7205364 | 0.95 | CA12 (0.64) | CA12CA2CA9ALOX15ALDH1A1 | |
| SCHEMBL7207746 | 0.95 | CA12 (0.64) | CA12CA2CA9ALOX15ALDH1A1 | |
| SCHEMBL7203875 | 0.95 | CA12 (0.64) | CA12CA2CA9ALOX15ALDH1A1 | |
| SCHEMBL7092423 | 0.95 | CA12 (0.64) | CA12CA2CA9ALOX15ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250107432-A1 | DIVALENT EUROPIUM-ORGANIC COORDINATION COMPOUND AND METHOD FOR PRODUCING THE SAME | BEEOLED GMBH (DE) | 2025-03-27 | — | — | US | disclosed |
| US-6605645-B2 | Such as 1,15-di(cyclopropylmethylamino)-8-benzyl-4,8,12-triazapentadecane; carcinostatic action | RIKEN (JP) | 2003-08-12 | — | — | US | disclosed |
| JP-2000184886-A | RNA POLYMERASE TRANSCRIPTION PROMOTER AND METHOD OF DETERMINING BASE SEQUENCE | INST OF PHYSICAL & CHEMICAL RES | 2000-07-04 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250107432-A1 | DIVALENT EUROPIUM-ORGANIC COORDINATION COMPOUND AND METHOD FOR PRODUCING THE SAME | ORC3, OR10J3, OSTC | CA12 59/4885CA2 640/4885CA9 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.